{
    "clinical_study": {
        "@rank": "121279", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the potential interactions between intravenous\n      methamphetamine and oral selegiline."
        }, 
        "brief_title": "Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1", 
        "completion_date": "October 2002", 
        "condition": "Amphetamine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Amphetamine-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "To determine the safety of the selegiline concurrent with d-methamphetamine challenges of\n      15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v.\n      methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm\n      study design to evaluate the safety of selegiline treatment, compared to placebo treatment,\n      concurrent with i.v. methamphetamine challenges."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence;\n             non-treatment seeking individuals\n\n          -  Be able to verbalize understanding of consent form; provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Please contact site for more information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "16", 
        "firstreceived_date": "April 5, 2002", 
        "id_info": {
            "nct_alias": "NCT00024882", 
            "nct_id": "NCT00033072", 
            "org_study_id": "NIDA-CTO-0004-1"
        }, 
        "intervention": {
            "intervention_name": "Selegiline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methamphetamine", 
                "Selegiline"
            ]
        }, 
        "lastchanged_date": "October 23, 2007", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90024"
                }, 
                "name": "UCLA Integrated Substance Abuse Program"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline", 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Thomas Newton, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": [
            {
                "measure": "safety of selegiline"
            }, 
            {
                "measure": "pharmacokinetic assessment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033072"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2003"
    }, 
    "geocoordinates": {
        "UCLA Integrated Substance Abuse Program": "34.052 -118.244"
    }
}